Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.

The proportion of patients recovered was higher in the BIO101 group than placebo and the proportion of patients who died was lower, however these differences did not reach statistical significance.

also in 111,027 other papers